OptiNose, Inc. is a commercial-stage biopharmaceutical company headquartered in Yardley, Pennsylvania, that focuses on the development and commercialization of novel treatments for ear, nose and throat (ENT) diseases. Since its founding in 2004, OptiNose has built a platform technology that harnesses the patient’s own exhalation to deliver drug formulations directly to targeted regions within the nasal cavity. The company went public in 2015 and has since concentrated its efforts on addressing unmet needs in chronic sinonasal conditions.
The company’s lead product, XHANCE, is an FDA-approved intranasal spray that utilizes OptiNose’s proprietary exhalation delivery system to treat chronic rhinosinusitis with and without nasal polyps. By directing active drug particles past the nasal valve and into the sinuses, XHANCE aims to reduce inflammation and improve sinus ventilation more effectively than traditional nasal sprays. Beyond XHANCE, OptiNose is advancing additional pipeline candidates for allergic rhinitis, nonallergic rhinitis and other ENT indications, all leveraging the same novel delivery approach.
OptiNose primarily serves the U.S. market with a specialized commercial organization focused on education and support for ear, nose and throat specialists, allergists and primary care physicians. The company is also pursuing regulatory approvals and partnerships in Europe and other regions to broaden patient access to its therapies. In parallel, OptiNose continually invests in clinical trials and research collaborations to expand the indications for its exhalation delivery platform.
Led by a seasoned management team with extensive experience in pharmaceutical development, regulatory affairs and commercial operations, OptiNose is guided by a board of directors with a track record in advanced drug delivery and ENT therapeutics. The company’s leadership emphasizes strategic growth initiatives, patient-centric innovation and rigorous clinical science as it works to reshape treatment paradigms in sinonasal and related disorders.
AI Generated. May Contain Errors.
